Company Overview and News

 
METALS-Copper heads for best week in a month as trade fears ease

2h reuters
MELBOURNE, Sept 21 (Reuters) - London copper rose on Friday and was on track to post its biggest weekly advance in four weeks as investors viewed that trade tariffs would have a softer impact to global growth than earlier feared.
BLT BHP BHPBF BBL BHP BHPLF

 
BHP / BHP Billiton Ltd. S-8

19h sec.gov
S-8 As filed with the Securities and Exchange Commission on September 20, 2018 Registration No. 333 -
BHP

2
ASX falls as supermarkets, banks wipe mining gains

23h theage.com.au
Australian shares closed lower on a volatile day of trading as the supermarkets and banks wiped gains made by the materials sector.
NCMGF NCM RIO BLT RIO BHPBF RTPPF NCMGY BHP RIO RTNTF BBL BHP MS BHPLF EHE

2
ASX falls as supermarkets, banks wipe mining gains

23h smh.com.au
Australian shares closed lower on a volatile day of trading as the supermarkets and banks wiped gains made by the materials sector.
NCMGF NCM RIO BLT RIO BHPBF RTPPF NCMGY BHP RIO RTNTF BBL BHP MS BHPLF EHE

 
Build a premiership portfolio

2018-09-20 ntnews.com.au
IT’S FOOTBALL finals time when we watch in awe as the best teams in the AFL and the NRL battle it out for the 2018 Premiership.
MQBKY WOPEF BLT BHPBF NST JIN IEL MCQEF CHEOY WPL LOV MAYNF WOPEY NESRF CMXHF BHP BBL CHEOF BHP NHRNY MQG BHPLF

1
U.S. Shale Gas: The Times They Are A-Changin' Chapter II: New Plays

2018-09-19 seekingalpha
A cursory look at three new Texas gas plays which will be adding supply to a crowded market.
APA BLT BHP BHPBF BBL BHP BHPLF

2
ASX hits two-week high as miners advance

2018-09-19 theage.com.au
Australian shares advanced amid more positive trade headlines as the major banks and miners lifted the market to its highest close in two weeks.
RIO BLT RIO LYSCF KMD REG RTPPF RTNTF MS KMD KTHDY BHPBF TPPTY TPM OZMLF TPGTF BHP RIO LYSDY BBL BHP OZL BHPLF JRHHY EHE JHC

2
ASX hits two-week high as miners advance

2018-09-19 smh.com.au
Australian shares advanced amid more positive trade headlines as the major banks and miners lifted the market to its highest close in two weeks.
RIO BLT RIO LYSCF KMD REG RTPPF RTNTF MS KMD KTHDY BHPBF TPPTY TPM OZMLF TPGTF BHP RIO LYSDY BBL BHP OZL BHPLF JRHHY EHE JHC

61
Sino-US Trade Relations Turn Sour: Winners & Losers

2018-09-18 zacks
President Trump’s administration has announced massive tariffs on Chinese imports, perhaps a move toward a full-fledged trade war with China.
ROP AYI BLT TXN BHPBF MDP WMT AYI.WI BABA INTU AMZN BHP MDPEB AAPL BBL BHP CSX BHPLF ROK

 
BHP / BHP Billiton Ltd. FORM 20-F

2018-09-18 sec.gov
Form 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
BHP

 
BHP / BHP Billiton Ltd. FORM 20-F

2018-09-18 sec.gov
Form 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
BHP

 
BHP / BHP Billiton Ltd. IRANNOTICE

2018-09-18 sec.gov
IRANNOTICE <
BHP

 
BHP / BHP Billiton Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-09-18 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
BHP

 
BHP / BHP Billiton Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-09-18 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
BHP

 
BHP / BHP Billiton Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-09-18 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
BHP

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 088606108